Hormone Refractory Prostate Cancer Clinical Trial
Official title:
Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients
Docetaxel (75mg/m2 q21d) is standard of care for patients with hormone refractory prostate
cancer (HRPC). Recent data indicate, that chemotherapeutics given at MTD induce, besides
their cytotoxic effects, mobilization of circulating endothelial cells (CEC) and -
progenitors (CEP) in drug-free breaks of each cycle. In preclinical models, mobilized
CEC/CEP result in tumor vasculogenesis and progression of disease.
We hypothesize that treatment with sunitinib, an anti-angiogenic tyrosine kinase inhibitor,
in between 3 weekly docetaxel disrupts CEC/CEP spikes following docetaxel leading to
chemosensitization and reduced tumor re-growth in HRPC patients responding to docetaxel.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00069745 -
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
|
Phase 3 | |
| Completed |
NCT01260688 -
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
|
Phase 2 | |
| Completed |
NCT00571675 -
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
|
Phase 2 | |
| Withdrawn |
NCT02867345 -
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
|
||
| Completed |
NCT01741116 -
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
|
Phase 2 | |
| Terminated |
NCT00525408 -
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00667199 -
BAY88-8223, Does Response Study in HRPC Patients
|
Phase 2 | |
| Recruiting |
NCT02955082 -
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
|
Phase 2 | |
| Recruiting |
NCT01590498 -
Radiotherapy vs Observation for CRPC
|
N/A | |
| Completed |
NCT01518283 -
Study of Weekly Cabazitaxel for Advanced Prostate Cancer
|
Phase 2 | |
| Terminated |
NCT00906243 -
RNActive®-Derived Therapeutic Vaccine
|
Phase 1/Phase 2 | |
| Terminated |
NCT00493766 -
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
|
Phase 1 | |
| Terminated |
NCT01083615 -
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
|
Phase 3 | |
| Completed |
NCT00987753 -
Study Evaluating the Safety and Tolerability of L-377202
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02208583 -
Molecular Phenotype Changes and Personalized Treatment for CRPC
|
N/A | |
| Completed |
NCT00928252 -
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00699751 -
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
|
Phase 3 | |
| Recruiting |
NCT00411853 -
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00448734 -
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00510718 -
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
|
Phase 1 |